Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805498 | 1.00 | PTGER4 (0.66) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30493974 | 0.91 | CYP1A2 (0.70) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14584207 | 0.91 | PTGER4 (0.60) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3500587 | 0.91 | CYP1A2 (0.70) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14584219 | 0.91 | CYP1A2 (0.60) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11316855 | 0.90 | PTGER4 (0.71) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24273636 | 0.90 | PTGER4 (0.59) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1218213 | 0.90 | PTGER4 (0.71) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30493910 | 0.90 | PTGER4 (0.59) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL11317467 | 0.90 | PTGER4 (0.59) | PTGER4CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103923765-A | Detergent Composition For Process Of Manufacturing Semiconductors And Displays | COWON INNOTECH INC | 2014-07-16 | — | — | CN | claimed |
| US-4282237-A | Method with substituted 1-benzyl-1H-indazole-3-carboxylic acids for interrupting pregnancy in mammals | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1981-08-04 | — | — | US | claimed |
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | METREA BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | Translatum Medicus Inc. (CA) | 2023-09-12 | — | — | US | disclosed |
| CN-110088103-B | Novel tetrahydropyridopyrimidine compounds for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-10968217-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3535262-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200062747-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3535262-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-09-05 | — | — | US | disclosed |
| US-4999367-A | Analgesics | AZIENDE CHIMICHE RUINITE ANGELINI FRANCESCO A. C. R. A. F. S. P. A. (IT) | 1991-03-12 | — | — | US | disclosed |
| CN-1044810-A | Ethers of 1-benzyl-3-hydroxymethyl-indazole and aliphatic-2-hydroxy acids | ACRAF (IT) | 1990-08-22 | — | — | CN | disclosed |
| EP-0382276-A2 | Ethers of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxyacids | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (IT) | 1990-08-16 | — | — | EP | disclosed |
| WO-1989006651-A1 | 1H-INDAZOLE-3-ACETIC ACIDS AS ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1989-07-27 | — | — | WO | disclosed |
| EP-0325375-A1 | 1H-indazole-3-acetic acids as aldose reductase inhibitors | PFIZER INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| US-4282237-A | Method with substituted 1-benzyl-1H-indazole-3-carboxylic acids for interrupting pregnancy in mammals | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1981-08-04 | — | — | US | disclosed |
| US-4282237-A | Method with substituted 1-benzyl-1H-indazole-3-carboxylic acids for interrupting pregnancy in mammals | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1981-08-04 | — | — | US | disclosed |
| US-3895026-A | Substituted 1-benzyl-1h-indazole-3-carboxylic acids and derivatives thereof | ACRAF | 1975-07-15 | — | — | US | disclosed |
| US-3895026-A | Substituted 1-benzyl-1h-indazole-3-carboxylic acids and derivatives thereof | ACRAF | 1975-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968217-B2 | Tetrahydropyridopyrimidines for the treatment and prophylaxis of hepatitis B virus infection | TPMT, DPYD, HAVCR2 | PTGER4 1695/4885CYP1A2 33/4885CYP3A4 28/4885 |
| US-11753382-B2 | Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives | PCMT1, ICMT, FNTA | PTGER4 4475/4885CYP1A2 594/4885CYP3A4 608/4885 |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | PTGER4 137/4885CYP1A2 3161/4885CYP3A4 1239/4885 |
| US-20200062747-A1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TPMT, DPYD, HAVCR2 | PTGER4 1813/4885CYP1A2 32/4885CYP3A4 25/4885 |
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | LPL, LIPA, PNLIP | PTGER4 1215/4885CYP1A2 973/4885CYP3A4 896/4885 |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | PTGER4 100/4885CYP1A2 3086/4885CYP3A4 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.